The global mRNA Therapy market size was valued at USD 37580 million in 2023 and is forecast to a readjusted size of USD 86420 million by 2030 with a CAGR of 12.6% during review period.
By delivering mRNA into a cell, the cell could be induced to produce any protein encoded by the mRNA. The protein produced can be used for medical prevention or treatment. The translatability and stability of mRNA as well as its immunostimulatory activity are the key factors to be optimized for specific therapeutic application. mRNA holds the potential to revolutionize vaccination, protein replacement therapies, and the treatment of genetic diseases.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report includes an overview of the development of the mRNA Therapy industry chain, the market status of mRNA Targeted Delivery in vivo (Vaccine, Drugs), Genetically Modified T cells (Vaccine, Drugs), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of mRNA Therapy.
Regionally, the report analyzes the mRNA Therapy markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global mRNA Therapy market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the mRNA Therapy market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the mRNA Therapy industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Vaccine, Drugs).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the mRNA Therapy market.
Regional Analysis: The report involves examining the mRNA Therapy market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the mRNA Therapy market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to mRNA Therapy:
Company Analysis: Report covers individual mRNA Therapy players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards mRNA Therapy This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (mRNA Targeted Delivery in vivo, Genetically Modified T cells).
Technology Analysis: Report covers specific technologies relevant to mRNA Therapy. It assesses the current state, advancements, and potential future developments in mRNA Therapy areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the mRNA Therapy market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
mRNA Therapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Vaccine
Drugs
麻豆原创 segment by Application
mRNA Targeted Delivery in vivo
Genetically Modified T cells
Transforming Nanoparticles to Develop Immunotherapy for Cancer
Small Molecule Drugs Discovery
麻豆原创 segment by players, this report covers
Moderna
BioNTech
Pfizer
Arcturus Therapeutics Holdings Inc.
Astrazeneca
CureVac
Translate Bio
Regeneron Pharmaceuticals
Arcturus Therapeutics
Takeda Pharmaceutical Company
Novartis
Sanofi
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe mRNA Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of mRNA Therapy, with revenue, gross margin and global market share of mRNA Therapy from 2019 to 2024.
Chapter 3, the mRNA Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and mRNA Therapy market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of mRNA Therapy.
Chapter 13, to describe mRNA Therapy research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope of mRNA Therapy
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of mRNA Therapy by Type
1.3.1 Overview: Global mRNA Therapy 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global mRNA Therapy Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Vaccine
1.3.4 Drugs
1.4 Global mRNA Therapy 麻豆原创 by Application
1.4.1 Overview: Global mRNA Therapy 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 mRNA Targeted Delivery in vivo
1.4.3 Genetically Modified T cells
1.4.4 Transforming Nanoparticles to Develop Immunotherapy for Cancer
1.4.5 Small Molecule Drugs Discovery
1.5 Global mRNA Therapy 麻豆原创 Size & Forecast
1.6 Global mRNA Therapy 麻豆原创 Size and Forecast by Region
1.6.1 Global mRNA Therapy 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global mRNA Therapy 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America mRNA Therapy 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe mRNA Therapy 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific mRNA Therapy 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America mRNA Therapy 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa mRNA Therapy 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Moderna
2.1.1 Moderna Details
2.1.2 Moderna Major Business
2.1.3 Moderna mRNA Therapy Product and Solutions
2.1.4 Moderna mRNA Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Moderna Recent Developments and Future Plans
2.2 BioNTech
2.2.1 BioNTech Details
2.2.2 BioNTech Major Business
2.2.3 BioNTech mRNA Therapy Product and Solutions
2.2.4 BioNTech mRNA Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 BioNTech Recent Developments and Future Plans
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer mRNA Therapy Product and Solutions
2.3.4 Pfizer mRNA Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Pfizer Recent Developments and Future Plans
2.4 Arcturus Therapeutics Holdings Inc.
2.4.1 Arcturus Therapeutics Holdings Inc. Details
2.4.2 Arcturus Therapeutics Holdings Inc. Major Business
2.4.3 Arcturus Therapeutics Holdings Inc. mRNA Therapy Product and Solutions
2.4.4 Arcturus Therapeutics Holdings Inc. mRNA Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Arcturus Therapeutics Holdings Inc. Recent Developments and Future Plans
2.5 Astrazeneca
2.5.1 Astrazeneca Details
2.5.2 Astrazeneca Major Business
2.5.3 Astrazeneca mRNA Therapy Product and Solutions
2.5.4 Astrazeneca mRNA Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Astrazeneca Recent Developments and Future Plans
2.6 CureVac
2.6.1 CureVac Details
2.6.2 CureVac Major Business
2.6.3 CureVac mRNA Therapy Product and Solutions
2.6.4 CureVac mRNA Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 CureVac Recent Developments and Future Plans
2.7 Translate Bio
2.7.1 Translate Bio Details
2.7.2 Translate Bio Major Business
2.7.3 Translate Bio mRNA Therapy Product and Solutions
2.7.4 Translate Bio mRNA Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Translate Bio Recent Developments and Future Plans
2.8 Regeneron Pharmaceuticals
2.8.1 Regeneron Pharmaceuticals Details
2.8.2 Regeneron Pharmaceuticals Major Business
2.8.3 Regeneron Pharmaceuticals mRNA Therapy Product and Solutions
2.8.4 Regeneron Pharmaceuticals mRNA Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Regeneron Pharmaceuticals Recent Developments and Future Plans
2.9 Arcturus Therapeutics
2.9.1 Arcturus Therapeutics Details
2.9.2 Arcturus Therapeutics Major Business
2.9.3 Arcturus Therapeutics mRNA Therapy Product and Solutions
2.9.4 Arcturus Therapeutics mRNA Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Arcturus Therapeutics Recent Developments and Future Plans
2.10 Takeda Pharmaceutical Company
2.10.1 Takeda Pharmaceutical Company Details
2.10.2 Takeda Pharmaceutical Company Major Business
2.10.3 Takeda Pharmaceutical Company mRNA Therapy Product and Solutions
2.10.4 Takeda Pharmaceutical Company mRNA Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Takeda Pharmaceutical Company Recent Developments and Future Plans
2.11 Novartis
2.11.1 Novartis Details
2.11.2 Novartis Major Business
2.11.3 Novartis mRNA Therapy Product and Solutions
2.11.4 Novartis mRNA Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 Novartis Recent Developments and Future Plans
2.12 Sanofi
2.12.1 Sanofi Details
2.12.2 Sanofi Major Business
2.12.3 Sanofi mRNA Therapy Product and Solutions
2.12.4 Sanofi mRNA Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 Sanofi Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global mRNA Therapy Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of mRNA Therapy by Company Revenue
3.2.2 Top 3 mRNA Therapy Players 麻豆原创 Share in 2023
3.2.3 Top 6 mRNA Therapy Players 麻豆原创 Share in 2023
3.3 mRNA Therapy 麻豆原创: Overall Company Footprint Analysis
3.3.1 mRNA Therapy 麻豆原创: Region Footprint
3.3.2 mRNA Therapy 麻豆原创: Company Product Type Footprint
3.3.3 mRNA Therapy 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global mRNA Therapy Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global mRNA Therapy 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global mRNA Therapy Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global mRNA Therapy 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America mRNA Therapy Consumption Value by Type (2019-2030)
6.2 North America mRNA Therapy Consumption Value by Application (2019-2030)
6.3 North America mRNA Therapy 麻豆原创 Size by Country
6.3.1 North America mRNA Therapy Consumption Value by Country (2019-2030)
6.3.2 United States mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe mRNA Therapy Consumption Value by Type (2019-2030)
7.2 Europe mRNA Therapy Consumption Value by Application (2019-2030)
7.3 Europe mRNA Therapy 麻豆原创 Size by Country
7.3.1 Europe mRNA Therapy Consumption Value by Country (2019-2030)
7.3.2 Germany mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific mRNA Therapy Consumption Value by Type (2019-2030)
8.2 Asia-Pacific mRNA Therapy Consumption Value by Application (2019-2030)
8.3 Asia-Pacific mRNA Therapy 麻豆原创 Size by Region
8.3.1 Asia-Pacific mRNA Therapy Consumption Value by Region (2019-2030)
8.3.2 China mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America mRNA Therapy Consumption Value by Type (2019-2030)
9.2 South America mRNA Therapy Consumption Value by Application (2019-2030)
9.3 South America mRNA Therapy 麻豆原创 Size by Country
9.3.1 South America mRNA Therapy Consumption Value by Country (2019-2030)
9.3.2 Brazil mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa mRNA Therapy Consumption Value by Type (2019-2030)
10.2 Middle East & Africa mRNA Therapy Consumption Value by Application (2019-2030)
10.3 Middle East & Africa mRNA Therapy 麻豆原创 Size by Country
10.3.1 Middle East & Africa mRNA Therapy Consumption Value by Country (2019-2030)
10.3.2 Turkey mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE mRNA Therapy 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 mRNA Therapy 麻豆原创 Drivers
11.2 mRNA Therapy 麻豆原创 Restraints
11.3 mRNA Therapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 mRNA Therapy Industry Chain
12.2 mRNA Therapy Upstream Analysis
12.3 mRNA Therapy Midstream Analysis
12.4 mRNA Therapy Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Moderna
BioNTech
Pfizer
Arcturus Therapeutics Holdings Inc.
Astrazeneca
CureVac
Translate Bio
Regeneron Pharmaceuticals
Arcturus Therapeutics
Takeda Pharmaceutical Company
Novartis
Sanofi
听
听
*If Applicable.
